Pharmaceutical Commerce
Pharmaceutical Commerce - December 2025
Volume: 20
Issue: 6
Pharmaceutical Commerce - October 2025
Volume: 20
Issue: 5
Pharmaceutical Commerce - August 2025
Volume: 20
Issue: 4
Pharmaceutical Commerce - June 2025
Volume: 20
Issue: 3
Pharmaceutical Commerce - April 2025
Volume: 20
Issue: 2
Pharmaceutical Commerce - February 2025
Volume: 20
Issue: 1
Pharmaceutical Commerce - December 2024
Volume: 19
Issue: 6
Pharmaceutical Commerce - October 2024
Volume: 19
Issue: 5
Pharmaceutical Commerce - August 2024
Volume: 19
Issue: 4
Pharmaceutical Commerce - June 2024
Volume: 19
Issue: 3
Pharmaceutical Commerce - April 2024
Volume: 19
Issue: 2
Pharmaceutical Commerce - February 2024
Volume: 19
Issue: 1
Pharmaceutical Commerce - December 2023
Volume: 18
Issue: 6
Pharmaceutical Commerce - October 2023
Volume: 18
Issue: 5
Pharmaceutical Commerce - August 2023
Volume: 18
Issue: 4
Pharmaceutical Commerce - June 2023
Volume: 18
Issue: 3
Pharmaceutical Commerce - April 2023
Volume: 18
Issue: 2
Pharmaceutical Commerce - February 2023
Volume: 18
Issue: 1
Pharmaceutical Commerce - December 2022
Volume: 17
Issue: 6
Pharmaceutical Commerce - October 2022
Volume: 17
Issue: 5
Pharmaceutical Commerce - August 2022
Volume: 17
Issue: 4
Pharmaceutical Commerce - June 2022
Volume: 17
Issue: 3
Pharmaceutical Commerce - April 2022
Volume: 17
Issue: 2
Pharmaceutical Commerce - February 2022
Volume: 17
Issue: 1
Pharmaceutical Commerce - November 2021
Volume: 16
Issue: 4
Pharmaceutical Commerce - September 2021
Volume: 16
Issue: 3
Pharmaceutical Commerce - June 2021
Volume: 16
Issue: 2
Pharmaceutical Commerce - March 2021
Volume: 16
Issue: 1
Pharmaceutical Commerce - December 2020
Volume: 15
Issue: 4
Pharmaceutical Commerce - September 2020
Volume: 15
Issue: 3
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
BoomRx Expands Access to Oral Semaglutide and Tirzepatide Using Nanoemulsion Delivery
2
The Hidden Economics of Health Insurance Affordability
3
Pharma Pulse: Novartis Warns of Trade Fragmentation; Hospital M&A Hits Record Low; Copay Shock Warning
4
Evaluate’s 2026 Pharma Forecast Signals Cautious Recovery, Rising M&A, and GLP-1 Market Shifts
5